According to the U.S. Centers for Disease Control and Prevention (CDC), in 2016, the last year data is available, 245,299 new cases of breast cancer in women were reported and 41,487 women died of it. Or to put it another way, more than a quarter of a million women are diagnosed with breast cancer each year, which comes out to about 124 new cases out of every 100,000 women.
What is sometimes surprising, given advances in treatment, is that the number of diagnoses has gone up from 196,000 in 1999 to 245,299 in 2016. Some of this is related to an overall increase in the U.S. population and other aspects may be due to increased awareness and better detection rates.
Quite a bit of effort and resources are going into developing therapies for breast cancer. Increasingly, like many cancers, drugs are developed and approved for narrower and narrower indications as more genetic and hormonal markers are developed and it is determined which drugs are most effective for the cancer types. As Breast Cancer Awareness Month wraps up, BioSpace gathered some examples of recent breakthroughs in breast cancer treatment.
MacroGenics On October 23, MacroGenics announced topline data from the second pre-specified interim overall survival (OS) analysis of its Phase III SOPHIA trial of margetuximab in HER2-positive metastatic breast cancer who have previously received anti-HER2-targeted therapies. The drug is an immune-enhancing monoclonal antibody derived from MacroGenics Fc Optimization tech platform. In the intent-to-treat population, the median OS of patients receiving the drug and chemotherapy was prolonged by 1.8 months compared to patients receiving trastuzumab and chemotherapy.
Seattle Genetics On October 21, Seattle Genetics announced positive results from its HER2CLIMB PHASE III clinical trial of tucatinib in combination with trastuzumab and capecitabine compared to trastuzumab and capecitabine alone in locally advanced unresectable or metastatic HER2-positive cancer.
HER2-positive breast cancer has tumors with high levels of human epidermal growth factor receptor 2 (HER2), which promotes aggressive metastases. Of breast cancers diagnosed annually around the world, between 15% and 20% globally are HER2-positive.
The HER2CLIMB trial met the primary endpoint of progression-free survival (PFS), showing that adding tucatinib to the treatment regime was superior to trastuzumab and capecitabine alone. There was a 46% decrease in the risk of disease progression or death by adding tucatinib.
Tucatinib is also being studied in breast cancer with other drug combinations as well as colorectal cancer.
New Immunotherapy Approaches Researchers with the Washington University School of Medicine found that other T-cells than the killer T-cells usually stimulated in immunotherapies can improve on these therapies. The WU researchers focused on helper T-cells, whose job it is to recognize cancer as a threat and recruit killer T-cells.
Immunotherapy presents tremendous promise for cancer treatment, but we havent yet found a way to make it widely effective, said Robert D. Schreiber, the Andrew M. and Jane M. Bursky Distinguished Professor, and senior author of the study. It still doesnt work for many patients, particularly for common cancers, such as breast or prostate. We want to understand why they are ineffective in these cases so we can make better therapies. Our research suggests that immunotherapy is likely to be more effective when a vaccine is used alongside checkpoint inhibitors.
The most effective anti-cancer response was observed when checkpoint inhibitors were combined with a vaccine that targets both helper and killer T-cells specific to the patients cancer cell antigens.
The idea of giving checkpoint inhibitors along with a tumor-specific vaccineespecially a vaccine that activates both killer and helper T-cellsis just beginning, Schreiber said. But based on our study, the combination is likely to be more effective than any of the components alone. Today, when we treat a particular tumor type with checkpoint inhibitors, maybe 20% of the patients respond well. Were hoping that with a vaccine plus checkpoint inhibitors, the number of patients who respond well will go up to 60 to 70%. We havent tried that yet in patients, but thats the hope.
New Approaches to Resistant Cancers Researchers at The Institute of Cancer Research (ICR), London, identified a drug that appears to be effective in cancers that become resistant to chemotherapy. The drug is called BOS172722 and it forces cancer cells to multiply faster, which would seem to be counterintuitive. However, this faster cell division causes more fatal errors in the cells. And in the case of this drug, appears to cause fatal errors in all the cancer cells.
We have discovered a brand new type of cancer treatment that uses cancers rapid growth against it, by forcing cells through cell division so quickly that they accumulate fatal errors, said Spiros Linardopoulos, Professor of Cancer Biology and Therapeutics at the ICR, who led the study. The drug works especially well in combination with chemotherapy in triple negative breast cancer cellsthe deadliest form of breast cancer for which there are few successful treatments.
Patients with triple-negative breast cancer generally receive taxane chemotherapies, such as paclitaxel. Paclitaxel affects chromosome distribution during cell division but prevents cells from dividingalso resulting in cell death. However, some cells develop resistance to the drug.
Cancer cells receiving paclitaxel and BOS172722 decrease cell division from about 110 minutes with paclitaxel alone to 15 minutes. All the cells treated with the combination had gross chromosome abnormalities and died, compared to 40% surviving with paclitaxel alone.
The drug also worked at lower doses when used in combination with paclitaxel, at least in lab animals, and was well tolerated by the mice.
Atossa Genetics In September, Atossa Genetics completed enrollment of its Phase I clinical trial of a proprietary modified-release oral tablet form of its Endoxifen. The trial has enrolled and endorsed 24 participates in the last six weeks. The company will use the Phase I dosing data to conduct a Phase II trial on whether the drug reduces breast density. Mammographic Breast Density (MBD) can mask the detection of cancers, and 35 states have legislation requiring women be notified if they have MBD, indicating that they have a higher risk of breast cancer and that mammography may not be as effective in detecting breast cancer as a result.
In August, Mustang Bio announced that City of Hope had received a $9.28 million grant from the California Institute for Regenerative Medicine (CIRM) to fund an ongoing Phase I trial of MB-103 in HER2-positive breast cancer with brain metastases. City of Hope holds patents covering the HER2 CAR that were licensed to Mustang Bio in 2017. The trial is expected to enroll 21 City of Hope patients with the primary objective to determine safety and dosing for intraventricular delivery of HER2-specific CAR-T cells.
SELLAS Life Sciences Group Also in August, SELLAS Life Sciences Group completed enrollment in its Phase II trial of nelipepimut-S (NPS) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in women with ductal carcinoma in situ (DCIS) of the breast who are HLA-A2+ or A3+ positive, express HER2 at IHC 1+, 2+, or 3+ levels, and are pre- or post-menopausal. The primary endpoint is the difference in frequency of newly induced NPS-cytotoxic T lymphocytes in peripheral blood between the two arms.
Merck In late July, Mercks checkpoint inhibitor Keytruda (pembrolizumab) hit the primary endpoint in the companys Phase III KEYNOTE-522 in triple-negative breast cancer (TNBC). Keytruda was used in combination with chemotherapy. The KEYNOTE-522 trial has 1,174 patients in it. It is a Phase III, randomized, double-blind trial studying Keytruda with chemotherapy compared to placebo plus chemotherapy as neoadjuvant therapy. The dual-primary endpoints are pathologic clinical response (pCR) and event free survival (EFS). Secondary endpoints are pCR rate, EFS in patients expressing PD-L1, overall survival, safety and patient-reported outcomes.
Novartis Also in late July, Novartis announced that its Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit its key secondary endpoint, overall survival, in a pre-planned interim analysis. The MONALEESA-3 trial is evaluating the efficacy and safety of Kisqali plus fulvestrant in postmenopausal women with HR+/HER2- advanced or metastatic breast cancer in the first-line and second-line treatment settings.
All of which suggests that intense research is ongoing in preventing and treating breast cancer, with improvements being developed every day.
Link:
Breast Cancer: Steady Progress Being Made in New Treatments - BioSpace
- No Rest For the Wicked | Review In Progress - XboxEra - April 27th, 2024 [April 27th, 2024]
- Maine made progress in wages and productivity, but still faces shrinking labor force - Press Herald - April 27th, 2024 [April 27th, 2024]
- The Progress Report: How 4 Schools Are Teaching Kids to Read and Seeing Success - Voice of San Diego - April 27th, 2024 [April 27th, 2024]
- PROGRESS MADE IN COLE REHAB? - Bleeding Yankee Blue - April 27th, 2024 [April 27th, 2024]
- Pollution or Progress? What's Next for LNG Development in the Rio Grande Valley - Progress Texas - April 27th, 2024 [April 27th, 2024]
- Lykos Therapeutics Makes Progress in Europe - The Dales Report - April 27th, 2024 [April 27th, 2024]
- Adelaide Film Fest Picks Five Works in Progress for Cannes Showcase, With Giant, Drafthouses Mockbuster Making the Cut (EXCLUSIVE) - Variety - April 27th, 2024 [April 27th, 2024]
- Washington says real progress needed before restoring UNRWA funding - The Times of Israel - April 27th, 2024 [April 27th, 2024]
- LIGA Provides Further Guidance: Engages Audit Firm and Making Progress in Search for CEO and Management Team - Yahoo Finance - April 27th, 2024 [April 27th, 2024]
- Forest Health Council Reports Progress Toward Community Wildfire Resiliency-Greg Felt Talks Wildfire Mitigation with ... - Heart of the Rockies Radio - April 27th, 2024 [April 27th, 2024]
- Football notes: Robert Livingston pleased with progress of CU Buffs defense - BuffZone - April 27th, 2024 [April 27th, 2024]
- Spencer Hospital Emergency Department Project Continuing to Progress - KICD - April 27th, 2024 [April 27th, 2024]
- Proof-of-Concept Exploit Released for Progress Software OpenEdge Vulnerability - The Hacker News - March 16th, 2024 [March 16th, 2024]
- Progress being made on fire alarms, Oswego town supervisor says - oswegocountynewsnow.com - March 16th, 2024 [March 16th, 2024]
- Progress on the Boyertown Express featured at Dinner - Berks Weekly - March 16th, 2024 [March 16th, 2024]
- Fire Crews Stop Forward Progress of Two-Acre Brush Fire Near Vandenberg - Santa Barbara Edhat - March 16th, 2024 [March 16th, 2024]
- Hopewell plans to install speed cameras at three city schools - Progress Index - March 16th, 2024 [March 16th, 2024]
- New numbers on progress of penny sales tax - The Post and Courier - March 16th, 2024 [March 16th, 2024]
- Long Island woman who survived acid attack continues to make progress in recovery - PIX11 New York News - March 16th, 2024 [March 16th, 2024]
- Beam marks progress toward bringing 1st-ever MLS team to San Diego - NBC San Diego - March 16th, 2024 [March 16th, 2024]
- McKone: Irish-American progress and paradoxes | Perspective | timesargus.com - Barre Montpelier Times Argus - March 16th, 2024 [March 16th, 2024]
- Big East reportedly making a lot of progress on media rights deals with CBS, Fox - Awful Announcing - March 16th, 2024 [March 16th, 2024]
- Berrien County farmers note slow progress on the new Farm Bill - News/Talk/Sports 94.9 WSJM - March 16th, 2024 [March 16th, 2024]
- END OF SESSION: Sen. Crider and Rep. Cherry reflect on progress made during the legislative session - Greenfield Daily Reporter - March 16th, 2024 [March 16th, 2024]
- Vowles being patient with Sargeant but expects to see "progress" - RaceFans - March 16th, 2024 [March 16th, 2024]
- Inflation ticked up in February, reversing some prior progress - ABC News - March 16th, 2024 [March 16th, 2024]
- Latest NEOM progress video of The Line is indicator of scale - Supercar Blondie - March 16th, 2024 [March 16th, 2024]
- Statewide Impact of Ohio Intel ProjectEvident in Initial Progress Report - Scioto Post - March 16th, 2024 [March 16th, 2024]
- SpaceX makes significant progress with third Starship orbital test flight - TechCrunch - March 16th, 2024 [March 16th, 2024]
- UPDATE: Forward progress stopped on vegetation fire near Lompoc - KSBY News - March 16th, 2024 [March 16th, 2024]
- Lady Rattlers and Diamondbacks ready to roll - Progresstimes - March 16th, 2024 [March 16th, 2024]
- SpaceX celebrates major progress on the third flight of Starship - Ars Technica - March 16th, 2024 [March 16th, 2024]
- Helldivers 2 Galactic War live map: Track status and progress with this Liberty-approved web app - Windows Central - March 16th, 2024 [March 16th, 2024]
- Pittsburgh police will only respond to calls of in-progress emergencies as part of new staffing plan - Police News - March 16th, 2024 [March 16th, 2024]
- A year of achievement, rebuilding and progress for utilities - Yoursun.com - March 16th, 2024 [March 16th, 2024]
- Trkiye: No Direct Dialogue with Damascus, No Progress in Normalization - Asharq Al-awsat - English - March 16th, 2024 [March 16th, 2024]
- A WORK IN PROGRESS | News | shelbynews.com - Shelbynews - March 16th, 2024 [March 16th, 2024]
- From recurrent networks to GPT-4: Measuring algorithmic progress in language models - Tech Xplore - March 16th, 2024 [March 16th, 2024]
- U.S. Inability To Address Nuclear Waste Harms Environmental Progress - Newsweek - March 16th, 2024 [March 16th, 2024]
- Park Progress - Greater Wilmington Business Journal - March 16th, 2024 [March 16th, 2024]
- SF supervisor to hold hearing on homeless-shelter progress | Housing | sfexaminer.com - San Francisco Examiner - March 16th, 2024 [March 16th, 2024]
- 'It's good to see progress being made on the site': Revised vision for Liberty Theater property in Libertyville - Daily Herald - March 16th, 2024 [March 16th, 2024]
- Diversity Among Emmy Winners Is a Result of Industry Progress - TheWrap - January 18th, 2024 [January 18th, 2024]
- What would Dr. King say about progress and 2024? - The Chicago Cusader - January 18th, 2024 [January 18th, 2024]
- Police: Petersburg woman reportedly used hammer to hit her boyfriend - Progress Index - January 18th, 2024 [January 18th, 2024]
- Spokane County crews make great progress ahead of another storm system - AOL - January 18th, 2024 [January 18th, 2024]
- Lady Tigers Split Last Weeks Game's Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Lexington Police Investigate Shooting at Walmart Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Scotts Hill Lions Dominated Last Week Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Older Couple Rescued From Submerged Vehicle Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Fore-ward Progress | Bintelli's new River Ridge facility to focus on making electric golf carts - WDRB - January 18th, 2024 [January 18th, 2024]
- VIDEO: Project manager gives update on Glenn McConnell Widening progress - Live 5 News WCSC - January 18th, 2024 [January 18th, 2024]
- Truck driver sentenced for trafficking cocaine to Prince George County - Progress Index - January 18th, 2024 [January 18th, 2024]
- After decades of little progress, Milwaukee begins new approach to improve lives of Black men and boys - madison365.com - January 18th, 2024 [January 18th, 2024]
- Women are bored of waiting: Slow progress on shattering the glass ceiling on company boards - I by IMD - I by IMD - January 18th, 2024 [January 18th, 2024]
- Now Accepting Applications for the 2024 Progress Software Mary Szkely Scholarship for Women in STEM - GlobeNewswire - January 18th, 2024 [January 18th, 2024]
- "Some progress made" at Onslow BOE meeting, according to number of parents - WCTI12.com - January 18th, 2024 [January 18th, 2024]
- Spokane County crews make great progress ahead of another storm system - Nonstop Local - January 18th, 2024 [January 18th, 2024]
- DeSantis took credit for Florida's progress but Iowa may have sniffed out his bravado | Opinion - Yahoo News Canada - January 18th, 2024 [January 18th, 2024]
- Has the Israeli Military Made Progress in Its Goal of Destroying Hamas? : State of the World from NPR - NPR - January 18th, 2024 [January 18th, 2024]
- Jan. 19 Panel Examines 30-Year Progress of Women in Research - Mirage News - January 18th, 2024 [January 18th, 2024]
- Ducks' Midseason Check-in: Progress, Improvement Areas & More - The Hockey Writers - January 18th, 2024 [January 18th, 2024]
- Companies are hiding their climate progress. A new report explains why. - Grist - January 18th, 2024 [January 18th, 2024]
- Lou Leonatti With Progress Mexico Gives Hospital Bankruptcy Hearing Update On AM 1340 KXEO Am I Awake Morning Show - KXEO - January 18th, 2024 [January 18th, 2024]
- Seaside Heights Wants to See Progress From Developers, Will Investigate 'Bamboo' Property - Shorebeat - January 18th, 2024 [January 18th, 2024]
- Progress over perfection: Is Coach modelling a path for fashion transformation? - Vogue Business - January 18th, 2024 [January 18th, 2024]
- Watch the video of the Edmonds armed robbery in progress - MyNorthwest - January 18th, 2024 [January 18th, 2024]
- Albemarle County house burns to the ground in late night fire - The Daily Progress - January 18th, 2024 [January 18th, 2024]
- GHDDI and Microsoft Research use AI technology to achieve significant progress in discovering new drugs to treat ... - Microsoft - January 18th, 2024 [January 18th, 2024]
- Henderson County Suspects Apprehended in Trenton Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- HCFD Reports Lowest Number of Residential Fires - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Unlocking The Future: CAGA's Progress In Web3 And Blockchain Innovation - Benzinga - January 18th, 2024 [January 18th, 2024]
- Underwhelming performance: Quarterbacks still a work in progress - Daily O'Collegian - September 3rd, 2023 [September 3rd, 2023]
- Governor Hochul Announces Progress in Increasing MTA Accessibility - ny.gov - September 3rd, 2023 [September 3rd, 2023]
- A progress report: The columnist's garden in September - Kennebec Journal and Morning Sentinel - September 3rd, 2023 [September 3rd, 2023]
- September 2023: Innovative researchers celebrate scientific ... - Environmental Factor Newsletter - September 3rd, 2023 [September 3rd, 2023]
- Progress over perfectionism - Lynn University - September 3rd, 2023 [September 3rd, 2023]
- Signs of progress on new Folsom Medical Office Building - UC Davis Health - September 3rd, 2023 [September 3rd, 2023]
- LA District FUDS team makes progress on Nellis Remedial Action ... - spl.usace.army.mil - September 3rd, 2023 [September 3rd, 2023]
- UFC Fight Night 226 winner Volkan Oezdemir pleased with progress after training with Khamzat Chimaev - Yahoo Sports - September 3rd, 2023 [September 3rd, 2023]